Clinical Trials Directory

Trials / Unknown

UnknownNCT04674475

OPTImized Coronary Interventions eXplaIn the bEst cliNical outcomEs

Status
Unknown
Phase
Study type
Observational
Enrollment
1,000 (estimated)
Sponsor
Spanish Society of Cardiology · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hypothesis: the clinical outcome of patients with indication of PCI and coronary stent implantation that are at high risk of events can be improved with a widespread use of intra-coronary tools that allow a PCI optimization (i.e. functional assessment by pressure guidewire and intra-coronary imaging techniques). Objective: to evaluate whether the use of pressure guidewire and intra-coronary imaging techniques (mainly optimal coherence tomography) in patients at high risk of events undergoing coronary angiography for myocardial revascularization is associated with an improved clinical outcome in comparison with patient with angiographic alone guided cobalt-chromium everolimus-eluting coronary stenting. Methods: Prospective observational multicentric international study with a follow-up of 12 months, including 1.000 patients in 40 sites located in 3 European countries (Spain, France, and Portugal). The control group will be comprised by a similar number of matched patients included in the "extended-risk" cohort of the XIENCE V USA study. PCI will be performed following local standard protocols and accordingly to the physician criteria. The use of pressure guidewire will be recommended according to the current guidelines, in patients with angiographically intermediate lesions and in those with multivessel disease. The use of OCT will be strongly recommended, as patients included will be considered to be at high risk of events, accordingly to the current recommendations. The primary endpoint will be target lesion failure (TLF) at 1 year.

Conditions

Interventions

TypeNameDescription
DEVICEPressure guidewire, optimal coherence tomographyPressure guidewire, optimal coherence tomography

Timeline

Start date
2021-05-03
Primary completion
2022-05-31
Completion
2023-06-16
First posted
2020-12-19
Last updated
2020-12-19

Source: ClinicalTrials.gov record NCT04674475. Inclusion in this directory is not an endorsement.